The study investigates the effectiveness of prophylactic gabapentin in reducing oral mucositis pain and managing opioid use for patients with oropharyngeal cancer receiving chemoRT.
It was a double-blind, randomized phase 3 trial with patients assigned to either gabapentin or placebo, measuring outcomes through patient-reported surveys over the treatment period.
Results showed no significant difference in oral mucositis symptom scores between gabapentin and placebo groups, although a notable decline in quality of life scores was observed in the functional well-being index.